KLRC1 and neoplasm: Multiple investigations have uncovered the inhibitory checkpoint inhibitors expressed on NK cells in tumor microenvironment, including the famous PD-1, CTLA-4 as well as newly identified NKG2A, TIGIT [44, 72], which are now appreciated as promising targets for NK cells-based immunotherapy.